Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Misses Expectations By $0.01 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its quarterly earnings results on Thursday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01), Zacks reports. The firm had revenue of $14.97 million for the quarter.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS opened at $0.99 on Friday. The firm has a market cap of $39.83 million, a PE ratio of -0.66 and a beta of -0.80. The firm’s 50 day moving average price is $1.01 and its 200 day moving average price is $1.12. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.